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Purpose: To evaluate the safety and efficacy of intravitreal injections of bevacizumab (Avastin®) 
as a treatment option for radiation maculopathy secondary to proton beam radiotherapy for 
choroidal melanoma.
Case: A 61-year-old woman presented with a gradual decrease in left eye visual acuity 
(VA) 29 months after proton beam radiotherapy for choroidal melanoma. On presentation, 
her best-corrected VA (BCVA) was 2/10 in the left eye and the intraocular pressure was 
15 mmHg. Fundoscopy revealed cystoid macular edema, intraretinal hemorrhages, epiretinal 
membrane in the posterior pole, and residual tumor scar with exudative retinal detachment and 
hard exudates in the periphery of the superotemporal quadrant. A treatment with intravitreal 
injections of bevacizumab (Avastin®) was recommended. The injections were performed on a 
six-weekly basis.
Results: The central retinal thickness prior to the treatment was 458 µm. After the first 
intravitreal injection of bevacizumab, the retinal thickness at the centre of the fovea was reduced 
to 322 µm. After the third injection, the central retinal thickness was 359 µm and 18 months after 
presentation, it reduced to 334 µm. The BCVA increased to 3/10 after the intravitreal injections 
of bevacizumab and remained stable during the follow-up period. The intraocular pressure was 
within normal range during the follow-up period.
Conclusion: Bevacizumab should be regarded as a treatment option for macular edema due to 
proton beam radiotherapy for choroidal melanoma. By reducing the central retinal thickness, 
intravitreal bevacizumab can improve VA or ameliorate further decline caused by radiation 
maculopathy.
Keywords: bevacizumab (Avastin®), choroidal melanoma, macular edema, radiation 
retinopathy
Case report
A 61-year-old woman presented with a gradual decrease in left eye visual acuity 
(VA) 29 months after proton beam radiotherapy for choroidal melanoma. On 
presentation, her best-corrected visual acuity (BCVA) was 2/10 in the left eye and 
intraocular pressure was 15 mmHg. Ophthalmoscopy revealed cystoid macular 
edema, intraretinal hemorrhages and epiretinal membrane. Residual tumor with 
scar, exudative retinal detachment, and hard exudates were seen in the superotem-
poral periphery.
The patient was evaluated by fluorescein angiography and optical coherence 
tomography (OCT), and intravitreal injections of 1.25 mg bevacizumab (Avastin®) 
were recommended.
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The patient was informed that the therapy was off-label 
and signed a relevant consent form.
The central retinal thickness before treatment was 458 µm 
(Figure 1) and a cystoid macular edema was evident on OCT 
and fluorescein angiography.
The procedure was carried out in the operation theatre. 
Topical proparacaine hydrochloride 0.5% was applied to the 
ocular surface followed by preparation with 5% povidone 
iodine. A cotton-tipped applicator soaked in proparacaine 
hydrochloride was applied to the injection site 4 mm pos-
terior to the limbus. The intravitreal dose of bevacizumab 
(Avastin®) was 1.25 mg and we performed an intravitreal 
injection every six weeks. Indirect ophthalmoscopy was used 
to confirm uneventful intravitreal placement. Six weeks after 
the first intravitreal injection of bevacizumab (Avastin®), 
the central retinal thickness was reduced to 322 µm. The 
VA improved to 3/10 and the intraocular pressure remained 
stable and a second injection was suggested. Six weeks after 
the second injection, the central retinal thickness increased 
to 377 µm, and the patient was re-evaluated by ophthalmos-
copy and OCT. A third intravitreal injection of bevacizumab 
was carried out and six weeks after the third injection, the 
central retinal thickness was reduced once again to 359 µm 
(Figure 2). The VA was 3/10 and the intraocular   pressure was 
14 mmHg. At this point, treatment was   discontinued and no 
further injections were recommended.
The patient was examined again 18 months after 
presentation. Her BCVA was 3/10 and intraocular pressure 
was 15 mmHg. Central retinal thickness was 334 µm, as 
documented by OCT (Figure 3). The ophthalmoscopic find-
ings were consistent with mild macular edema, epiretinal 
membrane, and residual tumor scar with exudative retinal 
detachment and hard exudates. The intraretinal hemorrhages 
have been absorbed.
Radiation retinopathy is a vision-threatening complication 
resulting from the therapeutic irradiation of ocular, orbital, 
periorbital, facial, nasopharyngeal, and cranial structures. 
It is a slow and progressive retinal microangiopathy with 
delayed-onset varying from 1 month to 15 years, but usually 
occurs within 3 years of treatment.1,2 Clinical manifestations 
of the disorder include macular edema and nonprolifera-
tive and proliferative retinopathy, similar to changes seen 
in diabetic retinopathy. The fundamental abnormality of 
chronic radiation damage is endothelial cell injury, pri-
marily in capillaries, followed by capillary closure (this 
can be revealed by fluorescein angiography), subsequent 
retinal ischemia, necrosis of nerve tissue, and fibrovascular 
proliferation.3
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Figure 2 Central foveal thickness after the third intravitreal bevacizumab injection.
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Figure 3 Central foveal thickness 18 months after presentation.Therapeutics and Clinical Risk Management
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Consequently, increased concentrations of vascular 
endothelial growth factor (VEGF) were found in treated 
and untreated eyes with uveal melanoma.4,5 The radiation 
macular edema can be treated with laser photocoagulation, 
photodynamic therapy, and intravitreal triamcinolone 
acetonide.6 The macular edema may also respond to 
anti-VEGF therapy.7,8 Bevacizumab is a recombinant 
humanized, full length, anti-VEGF monoclonal antibody 
that binds with all VEGF-A isoforms.
This case report suggests that cystoid macular edema, 
caused by proton beam radiotherapy for choroidal melanoma, 
responds to intravitreal injections of bevacizumab. This is 
shown by the reduction of the central retinal thickness on 
OCT. Also, anti-VEGF therapy seems to prevent further 
reduction and shows improved VA. The advantages of this 
treatment over the triamcinolone acetonide treatment are: 
the absence of intraocular pressure increase and cataract 
formation. Given that no serious side effects were observed, 
bevacizumab should be regarded as a treatment option for 
macular edema due to proton beam radiotherapy for choroidal 
melanoma.
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